Horm Metab Res
DOI: 10.1055/a-2411-9426
Yihan Zhao
1
Department of Endocrinology and Metabolism, Peking
University Peopleʼs Hospital, Beijing, China (Ringgold ID: RIN71185)
,
Fang Zhang
1
Department of Endocrinology and Metabolism, Peking
University Peopleʼs Hospital, Beijing, China (Ringgold ID: RIN71185)
,
Simin Zhang
1
Department of Endocrinology and Metabolism, Peking
University Peopleʼs Hospital, Beijing, China (Ringgold ID: RIN71185)
,
Xiaona Zhang
1
Department of Endocrinology and Metabolism, Peking
University Peopleʼs Hospital, Beijing, China (Ringgold ID: RIN71185)
,
Leili Gao
1
Department of Endocrinology and Metabolism, Peking
University Peopleʼs Hospital, Beijing, China (Ringgold ID: RIN71185)
,
Qian Ren
1
Department of Endocrinology and Metabolism, Peking
University Peopleʼs Hospital, Beijing, China (Ringgold ID: RIN71185)
,
Xueyao Han
1
Department of Endocrinology and Metabolism, Peking
University Peopleʼs Hospital, Beijing, China (Ringgold ID: RIN71185)
,
Linong Ji
1
Department of Endocrinology and Metabolism, Peking
University Peopleʼs Hospital, Beijing, China (Ringgold ID: RIN71185)
› Author AffiliationsSupported by:
Research and Development Fund of Peking University Peopleʼs
Hospital
RDL2022-20
› Further Information
Also available at
![SFX Search]()
Buy Article Permissions and Reprints
Abstract
Denosumab is a completely human monoclonal high-affinity antibody that binds to
the nuclear factor kappa-B ligand (RANKL) and is widely used to treat
osteoporosis. Furthermore, it can potentially lower serum calcium levels by
inhibiting osteoclast activation and preventing bone calcium from being released
into the blood. This review aimed to provide evidence of the efficacy and safety
of denosumab in treating hypercalcemia in primary hyperparathyroidism (PHPT).
PubMed and the Cochrane Library were searched for published studies that
described denosumab for hypercalcemia management in PHPT. Data were extracted by
two independent investigators and analyzed using SPSS 23. The risk of bias was
assessed by NIH Quality Assessment Tool. In total, 161 patients with PHPT from
18 studies were included in this review. The average age was 61 (47–72) years
and the highest serum calcium was 3.76 (3.11–4.20) mmol/l. We found that
denosumab can effectively reduce the serum calcium level by a median reduction
of 0.5 mmol/l within 3 days. Significant reduction was maintained for 14 days.
The serum calcium-lowering effect weakened after one month. In conclusion,
denosumab has a potential clinical value in treating hypercalcemia in patients
with PHPT.
Keywords
denosumab -
calcium homeostasis -
hypercalcemia -
hyperparathyroidism
Publication History
Received: 02 July 2024
Accepted after revision: 01 September 2024
Article published online:
11 October 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
References
1
Walker MD,
Silverberg SJ.
Primary hyperparathyroidism. Nat Rev Endocrinol 2018; 14: 115-125
2
Ziegler R.
Hypercalcemic crisis. J Am Soc Nephrol 2001; 12: S3-S9
3
Wilhelm SM,
Wang TS,
Ruan DT.
et al.
The American association of endocrine surgeons guidelines for definitive
management of primary hyperparathyroidism. JAMA Surg 2016; 151: 959-968
4
Pappachan JM,
Lahart IM,
Viswanath AK.
et al.
Parathyroidectomy for adults with primary hyperparathyroidism. Cochrane Database Syst Rev 2023; 3:
Cd013035
5
Cummings SR,
San Martin J,
McClung MR.
et al.
Denosumab for prevention of fractures in postmenopausal women with
osteoporosis. N Engl J Med 2009; 361: 756-765
6
Kendler DL,
Cosman F,
Stad RK.
et al.
Denosumab in the treatment of osteoporosis: 10 years later: a narrative
review. Adv Ther 2022; 39: 58-74
7
Bollerslev J,
Rejnmark L,
Zahn A.
et al.
European expert consensus on practical management of specific aspects of
parathyroid disorders in adults and in pregnancy: recommendations of the ESE
educational program of parathyroid disorders. Eur J Endocrinol 2022; 186: R33-R63
8
Eller-Vainicher C,
Palmieri S,
Cairoli E.
et al.
Protective effect of denosumab on bone in older women with primary
hyperparathyroidism. J Am Geriatr Soc 2018; 66: 518-524
9
Eremkina A,
Krupinova J,
Dobreva E.
et al.
Denosumab for management of severe hypercalcemia in primary
hyperparathyroidism. Endocr Connect 2020; 9: 1019-1027
10
Gronskaya S,
Belaya Z,
Rozhinskaya L.
et al.
Denosumab for osteoporosis in patients with primary hyperparathyroidism and
mild-to-moderate renal insufficiency. Endocrine 2023; 81: 368-378
11
Leere JS,
Karmisholt J,
Robaczyk M.
et al.
Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2020; 8: 407-417
12
Miyaoka D,
Imanishi Y,
Kato E.
et al.
Effects of denosumab as compared with parathyroidectomy regarding calcium,
renal, and bone involvement in osteoporotic patients with primary
hyperparathyroidism. Endocrine 2020; 69: 642-649
13
Çalapkulu M,
Gul OO,
Cander S.
et al.
Control of refractory hypercalcemia with denosumab in a case of metastatic
parathyroid carcinoma. J Coll Physicians Surg Pak 2020; 30: 757-759
14
Gill G,
Agrawal V,
Kerr P.
Primary hyperparathyroidism presenting as acute hypercalcemic crisis: a case
report. J Otolaryngol Head Neck Surg 2023; 52: 1
15
Jumpertz von Schwartzenberg R,
Elbelt U,
Ventz M.
et al.
Palliative treatment of uncontrollable hypercalcemia due to parathyrotoxicosis:
denosumab as rescue therapy. Endocrinol Diabetes Metab Case Rep 2015; 2015: 150082
16
Kuchay MS,
Mathew A,
Kaur P.
et al.
Denosumab can be used successfully as a bridge to surgery in patients with
severe hypercalcemia due to primary hyperparathyroidism. Arch Endocrinol Metab 2021; 65: 669-673
17
Lenherr-Taube N,
Lam CK,
Vali R.
et al.
Severe primary hyperparathyroidism caused by parathyroid carcinoma in a
13-year-old child; novel findings from HRpQCT. JBMR Plus 2020; 4: e10324
18
Li Y,
Fan CY,
Manni A.
et al.
Pitfalls of using denosumab preoperatively to treat refractory severe
hypercalcaemia. BMJ Case Rep 2020; 13: e233665
19
Makino H,
Notsu M,
Asayama I.
et al.
Successful control of hypercalcemia with sorafenib, evocalcet, and denosumab
combination therapy for recurrent parathyroid carcinoma. Intern Med 2022; 61: 3383-3390
20
Omi Y,
Yamamoto T,
Nagashima Y.
et al.
Parathyroid carcinoma in a 13-year-old girl with a long-term survival. Surg Case Rep 2020; 6: 145
21
Rajan R,
Cherian KE,
Kapoor N.
et al.
Denosumab as a bridge to surgery in a patient with severe hypercalcemia due to
primary hyperparathyroidism in the setting of renal dysfunction. Indian J Endocrinol Metab 2019; 23: 269-270
22
Roukain A,
Alwan H,
Bongiovanni M.
et al.
Denosumab for the treatment of hypercalcemia in a patient with parathyroid
carcinoma: a case report. Front Endocrinol (Lausanne) 2021; 12: 794988
23
Shalaby T,
Anandappa S,
Sivappriyan S.
et al.
The use of denosumab in a nonagenarian with primary hyperparathyroidism. Eur Endocrinol 2014; 10: 151-152
24
Tzotzas T,
Goropoulos A,
Karras S.
et al.
Effective long-term management of parathyromatosis-related refractory
hypercalcemia with a combination of denosumab and cinacalcet treatment. Hormones (Athens) 2022; 21: 171-176
25
Vellanki P,
Lange K,
Elaraj D.
et al.
Denosumab for management of parathyroid carcinoma-mediated hypercalcemia. J Clin Endocrinol Metab 2014; 99: 387-390
26
Kim SY,
Ok HG,
Birkenmaier C.
et al.
Can denosumab be a substitute, competitor, or complement to
bisphosphonates?. Korean J Pain 2017; 30: 86-92
27
Ahmad S,
Kuraganti G,
Steenkamp D.
Hypercalcemic crisis: a clinical review. Am J Med 2015; 128: 239-245
28
Allgrove J.
Biphosphonates. Arch Dis Child 1997; 76: 73-75
29
Perazella MA,
Markowitz GS.
Bisphosphonate nephrotoxicity. Kidney Int 2008; 74: 1385-1393
30
Body JJ,
Pfister T,
Bauss F.
Preclinical perspectives on bisphosphonate renal safety. Oncologist 2005; 10: 3-7
31
Chandran M,
Bilezikian JP,
Lau J.
et al.
The efficacy and safety of cinacalcet in primary hyperparathyroidism: a
systematic review and meta-analysis of randomized controlled trials and cohort
studies. Rev Endocr Metab Disord 2022; 23: 485-501
32
Manaka K,
Sato J,
Kinoshita Y.
et al.
Effectiveness and safety of cinacalcet for primary hyperparathyroidism: a single
center experience. Endocr J 2019; 66: 683-689
33
Peacock M,
Bolognese MA,
Borofsky M.
et al.
Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone
densitometric outcomes in a five-year study. J Clin Endocrinol Metab 2009; 94: 4860-4867
34
Raje N,
Terpos E,
Willenbacher W.
et al.
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed
multiple myeloma: an international, double-blind, double-dummy, randomised,
controlled, phase 3 study. Lancet Oncol 2018; 19: 370-381
35
Bandeira F,
Cusano NE,
Silva BC.
et al.
Bone disease in primary hyperparathyroidism. Arq Bras Endocrinol Metabol 2014; 58: 553-561
留言 (0)